Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37828429)

  • 1. Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
    Kuol N; Godlewski J; Kmiec Z; Vogrin S; Fraser S; Apostolopoulos V; Nurgali K
    BMC Cancer; 2023 Oct; 23(1):971. PubMed ID: 37828429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases Immunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer.
    Kuol N; Davidson M; Karakkat J; Filippone RT; Veale M; Luwor R; Fraser S; Apostolopoulos V; Nurgali K
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression.
    Jayathilake AG; Veale MF; Luwor RB; Nurgali K; Su XQ
    BMC Complement Med Ther; 2020 Dec; 20(1):372. PubMed ID: 33287803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
    Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
    Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 and PD-L2 expression in colorectal cancer.
    Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
    Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
    Pittet CL; Newcombe J; Prat A; Arbour N
    J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
    Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K
    Front Immunol; 2021; 12():767666. PubMed ID: 34899719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
    Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
    Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
    Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.